
Illustrative image. Catalogue strength: 5 mg / 5 mg; image label may differ.
CJC-1295 No DAC/Ipamorelin
A blended reference material containing CJC-1295 (modified GRF 1-29) and Ipamorelin, supplied for in-vitro laboratory research.
- Material
- CJC-1295 No DAC/Ipamorelin
- Form
- Lyophilized powder
- Vial quantity
- 5 mg / 5 mg · 1 vial
- Batch number
- BLD-501
- Testing status
- Report published
- Storage
- Store lyophilized material at -20 °C, protected from light. Once reconstituted, refrigerate at 2–8 °C and handle under standard laboratory practice.
Supplied for laboratory research use only. Not for human or veterinary use.
Latest Test Results
Batch: BLD-501
- Identity
- Reported components: CJC-1295 No DAC and Ipamorelin (HPLC-MS/MS).
- Quantity
- CJC-1295: 5.78 mg; Ipamorelin: 6.25 mg; laboratory-reported total net content: 12.04 mg (tested sample).
- Purity
- CJC-1295: 99.85%; Ipamorelin: 99.89% chromatographic purity (tested sample).
- Additional testing
- No endotoxin or sterility results supplied.
- Independent laboratory
- Peptide Test Canada / Side-Chain Analytics Inc.
- Testing date
- November 5, 2026
Laboratory sample ID BLD-501; report COA-2026-SC-04743; verification reference PTC-K487EXBD. Received October 29, 2026; analyzed and reported November 5, 2026. This record uses the laboratory sample ID, not a confirmed inventory lot number. Total net content is reproduced as reported by the laboratory; displayed rounded component values sum to 12.03 mg. Results apply only to the sample as received, not other vials or any entire lot or batch. They do not establish safety, efficacy, regulatory compliance, or suitability for human or veterinary use. Laboratory permission to display the full report was confirmed by the owner.
Batch archive
- BLD-501November 5, 2026View record →
- LAN-CI-2608-01—View record →
Material Overview
CJC-1295 / Ipamorelin is supplied as a blended peptide reference material. CJC-1295 (without DAC) is a modified growth hormone-releasing factor analogue; Ipamorelin is a synthetic pentapeptide studied as a growth hormone secretagogue receptor ligand. Each batch is submitted for independent analytical testing.
Research Context
Both molecules have been studied in the published literature in relation to growth hormone axis signalling in laboratory and animal models. Research findings do not constitute clinical evidence of efficacy in humans.
Storage & Handling
Store lyophilized material at -20 °C, protected from light. Once reconstituted, refrigerate at 2–8 °C and handle under standard laboratory practice.
Molecular Information
- Peptide sequence
- Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Molecular formula
- CJC-1295: C152H252N44O42 · Ipamorelin: C38H49N9O5
- Molecular weight
- CJC-1295: 3367.9 g/mol · Ipamorelin: 711.85 g/mol
- CAS number
- 863288-34-0 (CJC-1295) · 170851-70-4 (Ipamorelin)
- Synonyms
- Modified GRF (1-29); NNC 26-0161
- Research classification
- Peptide blend reference material
Common questions about CJC-1295 No DAC/Ipamorelin
- What purity is CJC-1295 No DAC/Ipamorelin tested to?
- Our specification is Reported per batch. Each lot's sample is sent to an independent third-party laboratory, and published reports apply only to the sample tested.
- How should CJC-1295 No DAC/Ipamorelin be stored?
- Store lyophilized material at -20 °C, protected from light. Once reconstituted, refrigerate at 2–8 °C and handle under standard laboratory practice.
- What strength and form is supplied?
- 5 mg / 5 mg per vial, supplied as lyophilized powder.
- Where does CJC-1295 No DAC/Ipamorelin ship from?
- Orders are processed and dispatched within Canada. Shipping is $22 CAD on orders under $300 and free at $300 or more.
- Is CJC-1295 No DAC/Ipamorelin for human use?
- No. It is sold strictly for laboratory research use only and is not for human or veterinary consumption.
